A triad of exophthalmos, pretibial myxedema and acropachy in a patient with Graves’ disease

Mirjana PARAVINA1*, Milenko STANOJEVIĆ1-2, Mirjana VELIČKOVIĆ3, Stanoje PETROVIĆ4, Mirjana. MILOSAVLJEVIĆ1

1Clinic of Skin and Venereal Diseases, Clinical Center of Niš, Serbia
2Center of Pathology, Clinical Center of Niš, Serbia
3Clinic of Endocrinology, Clinical Center of Niš, Serbia

*Correspondence: Mirjana Paravina, E-mail: mirjanaparavina@gmail.com

UDC 616.441-008.64-06:616.5

Abstract

A classical triad of extrathyroidal manifestations of Graves’ disease known as EMO syndrome (exophthalmos, pretibial myxedema and osteoarthropathy) is a rare condition. This paper presents a 39-year-old male patient who underwent chemo- and radiation therapy of the supradiaphragmatic area due to Hodgkin’s disease at the age of 35 and 36 leading to remission. Two years later, the patient developed general symptoms of Graves’ disease and ophthalmopathy, with high thyroid stimulating hormone levels. Four months later, the patient presented with pretibial myxedema. Thirteen months after the onset of the disease, higher levels of thyroxine and decreased levels of thyroid stimulating hormone were registered. The diagnosis of EMO syndrome was confirmed by radiologic and histopathological analyses. Thiamazole and intralesional corticosteroid therapy were administered, resulting in euthyreosis and decrease of pretibial myxedema.

The question is whether the autoimmune thyroid disease was triggered by the previous disease, or by chemo- and radiation therapy.

Key words

Graves’ Disease; Exophthalmos; Myxedema; Osteoarthropathy, Primary Hypertrophic; Syndrome

Back in 1786, Parry described the association between exophthalmos and goiter. Apart from these two manifestations, in 1935 Graves described thyrotoxicosis, and in 1840 Basedow described palpitations. Today, this disease is commonly called Graves’, or Graves’-Basedow disease (1).

It is a chronic autoimmune disease characterized by diffuse goiter, hyperthyreosis, ophthalmopathy and dermopathy (2). Hyperthyreosis affects 1-2% of women under the age of 40 years, whereas in men it is about ten times less common. It occurs in 0.3% of the general population, and out of this number, 4.3% have a subacute form of the disease (3).

Not all the abovementioned symptoms are always present, and others may occur as well. Thus, Thomas (in 1933) and Diamond (in 1959) described a triad of exophthalmos, pretibial myxedema and acral osteopathy, while Braun-Falco and Petzoldt suggested the term EMO syndrome (exophthalmos, pretibial myxedema and hypertrophic osteoarthropathy) in 1967 (4).

Out of extrathyroidal manifestations, ophthalmopathy, dermopathy and acropachy are most common. Pretibial myxedema is rarely an initial symptom of Graves’ disease (5). Ophthalmopathy affects about 30% of patients with Graves’ disease, dermopathy about 4%, and acropachy about 1% of patients (6). Symptoms of the disease occur independently of the production of thyroid hormones. Dermopathy was also described in euthyreosis (7, 8), and in hypothyreosis with subsequent hyperthyreosis (9). Cases of exophthalmos and myxedema in Hashimoto thyroiditis were reported as well (10), generally leading to hypothyreosis. There are opinions according to which all autoimmune thyroid
diseases are variants of one disease that has a predominant evolution in one direction or another (2).

**Case report**

This is a report of a 39-year old man, locksmith by profession, who underwent treatment of Hodgkin’s disease at the age of 35 and 36 with ABVD-MOPP [adriamycin, bleomycin, vinblastine, dacarbazine – mustargen (mechlorethamine HCl), oncovin (vincristine), procarbazine, and prednisone] principle of chemotherapy (6 cycles), and 10 cycles of radiation therapy of the supradiaphragmatic area (mantle field), 20 sessions of TD=36 Gy (Grays). This treatment regimen showed to be effective in inducing stable remission.

Two years later, the patient presented with eyelid swelling, eyeball extrusion, fatigue, anxiety, insomnia, and normal appetite and body weight. Normal levels of triiodothyronine (T3) and thyroxine (T4) were found, with increased levels of the thyroid stimulating hormone (TSH). Four month later, red lumps appeared on the patient’s shins and dorsal feet. Nine months after that, about 13 months from the onset of the disease, elevated levels of T4 and decreased levels of TSH were recorded. Tiamazol therapy was initiated, 10 mg per day. The patient visited a dermatologist two months later. Skin biopsy was collected from the lesion on the lower leg and a diagnosis of circumscribed pretibial myxedema was confirmed. Apart from exophthalmos and myxedema, the patient presented with lesions on distal fingers and clubbing (Hippocratic) nails. At that time, the patient lost 3kg.

**Objective examination:** the patient was of medium height and a little undernourished. He had bilateral exophthalmos with lid edema (Figure 1). His thyroid gland was firm and nodular on the left side. He also presented with asthenia of the thorax and a narrowed mid-vertebral space. Heart: the patient had extrasystolic arrhythmia, systolic heart murmur at the Erb’s point. Lungs and abdomen: without symptoms.

**Dermatological examination** showed lesions of the lower extremities (Figure 2) and dorsal feet (on the sites of old injury scars). The lesions were almost symmetrical, with clearly defined painless infiltrates and nodules of firm consistency. The skin showed mild erythema, uneven surface with orange peel appearance due to prominent hair follicles. The hair was rough and partly missing. The small hand joints were painful to touch, with drumstick fingers and watch glass nails (Figure 3.).

**Laboratory analyses:** at the onset of the disease the following results were established: T3: 1.9 mmol/l (normally 1.2 – 3.0); T4: 101.0 mmol/l (normally 55.0 – 165.0); TSH: 9.1 U/l (normally 0.17 – 4.05). Thirteen months after onset: T3: 3.2 mmol/l, T4: 257 mmol/l, TSH: 0.14 U/l. After two, three and four months, levels of T3, T4, TSH, thyroglobulin and anti-thyroglobulin antibodies were normal. Other test results were in the normal range.

**Ophthalmologic findings:** exophthalmos and subacute conjunctivitis.

**Radiological findings** of the hands and long bones: the x-ray showed acropachy with hyperostosis of the diaphyseal portion of phalanges of the index and middle fingers (Figure 4), the rest without symptoms. Ultrasound of the thyroid gland: the thyroid gland was of normal size (isthmus 3mm, the right lobe 19x21, the left lobe 17x21), of hypoechogenic and nonhomogenous structure, without visible nodules. Orbital computed tomography: the orbital bone was of normal diameter, contours, without morphologic structural alterations. Both bulbs were of normal position and structure. The retrobulbar spaces were unremarkable, and both optic nerves normal. Hypophysese computed tomography: sella turcica was of normal diameter with normal bone structures and without densimetric alterations.

**Histopathological findings:** the corneal layer and epidermis were without prominent changes...
Figure 2. Pretibial myxedema: bilateral, almost symmetrical, clearly defined painless infiltrates and nodules of firm consistency, showing mild erythema and uneven surface with orange peel appearance (Figure 5). The dermis layer was thickened and collagen fiber networks were cross-linked. Fibroblasts were present, within normal levels, some star-shaped. Mucin dermal deposits were scarce in the papillary and more prominent in the rest of the dermis, presenting between abundant collagen fibers.

Therapy
Favistan® (tiamazol) tablets of 20mg were used, 2 x 1, later 2 x ½. The treatment with topical corticosteroids showed no visible improvement. Intralesional hydrocortisone injections caused reduction of pretibial changes to some extent. Exophthalmos and acropachy remained unchanged. The patient's general condition was good all the time.

Discussion
The cause of Graves’ disease is unknown. A certain genetic predisposition is indicated by several family members suffering from the disease and its association with other autoimmune diseases, for example endocrine diseases (2).

Apart from heritage, other risk factors are evident as etiologic factors of Graves’ disease: smoking, immunosuppression, stress, some medications (for example amiodarone, interferon, lithium carbonate), iodine contrasts, radiation therapy of the neck, viral and bacterial infections, iodine insufficiency in the diet (4). Hyperthyroidism in Graves’ disease is due to the binding of stimulatory autoantibodies to the TSH receptor (TSHr) on thyroid follicular cells. The stimulation of this G protein coupled receptor by autoantibodies leads to excessive and uncontrolled production of thyroid hormone (11).

Development of extrathyroidal manifestations, such as ophthalmopathy and pretibial myxedema, is associated with positive feedback mechanisms including mechanical (trauma/pressure), immune (accumulation of immune cells, inflammatory cytokines, increased expression of TSHr) and cellular processes (adipogenesis, increased production of glycosaminoglycans/prostaglandin E.) (11). "A subclinical systemic inflammatory process might develop in Graves’ disease as activated T cells and

Figure 3. Clubbing of the fingernails: drumstick fingers and watch glass nails
IgG recognize TSHr expressed in connective tissues. More significant involvement of the orbits and lower extremities might result from the accumulation of edema and inflammatory cytokines in these particular regions. This pooling of inflammatory mediators might be facilitated by unique anatomical and mechanical features if these regions. As fibroblasts from these sites appear to be especially sensitive to cytokine stimulation of metabolic processes, the local production of glycosaminoglycans (GAG) and inflammatory mediators would increase. In addition, cytokines or other local factors might stimulate the differentiation of orbital precursor cells into mature adipocytes with increased expression of TSHr. This increase in target antigen expression might cause further propagation of the immunological process in the orbit and pretibial skin. Increased orbital fat and GAG production would probably cause further impairment of venous and lymphatic drainage from the orbits and lower extremities, resulting in progression of Graves' ophthalmopathy (GO) and pretibial dermatopathy (PTD)” (11).

Ophthalmopathy is the first extrathyroidal manifestation of Graves’ disease. In a study including 150 consecutive patients with pretibial myxedema, only one patient presented without ophthalmopathy (12). The clinical picture of this manifestation is characterized by proptosis, conjunctival injection, chemosis, diplopia, corneal ulcerations, and extreme cases of blindness due to optic nerve compression (13). Anti-TSHr antibodies correlate with clinical features of Graves’ ophthalmopathy. Anti-TSHr antibodies and orbital TSHr levels are clearly associated with Graves’ ophthalmopathy. The next extrathyroidal manifestation is pretibial myxedema or thyroidal dermopathy, which includes accumulation of GAG (glycosaminoglycans) in the dermis and subcutaneous tissue (15). It accounts for 10-12% of patients with Graves’ ophthalmopathy (12). Early lesions are bilateral, asymmetrical, with firm non-pitting edema, nodules or skin-colored, pink or purple papules. Late lesions develop by confluence of early lesions, symmetrically covering the pretibial region and may result in grotesque involvement of shins and feet. The skin is of orange-peel texture, sometimes even varicose. Depending on the clinical picture, several forms of dermopathy are described: nodular, diffuse and elephantianthiac (17).
intravenous immunoglobulins); plasmapheresis and somastatin analogues such as octreotide (insulin-like growth factor type-1-antagonist); systemic immunomodulators are used for regression of skin lesions (18); radiation therapy is also used, while surgical orbital decompression is used in the correction of exophthalmos, and surgery of extraocular muscles in the correction of diplopia (23).

Potent topical corticosteroids under occlusion may be used in the treatment of mild forms of pretibial myxedema. Oral use of pentoxifylline and topical use of clobetasol propionate are recommended for the improvement of myxedema and ophthalmopathy (24). In severe forms of myxedema, intralesional corticosteroids are used, which had positive effects in our patient; compression and complete decongestive physiotherapy are also used (25) as well as CO₂ laser (7); surgical ablation and intravenous immunoglobulins are used in severe cases (26). In severe refractory pretibial myxedema, a combination of surgery and octreotide is performed (27), or intralesional octreotide (28).

Anyhow, the course of the disease does not only depend on applied medications, but also on the immune status of patients. Long-term remissions are possible, and in mild cases complete regressions as well.

**Conclusion**

This is a case report of a patient who developed exophthalmos, pretibial myxedema and hyperthyreosis after chemo- and radiation therapy of the supradiaphragmatic area due to Hodgkin's disease. Osteoarthropathy developed in the end, causing EMO syndrome. The applied therapy induced euthyreosis and regression of myxedema, but did not affect ophthalmopathy and acropachy.

**Abbreviations**

- EMO syndrome - The combination of exophthalmos, pretibial myxoedema and hypertrophic osteoarthropathy
- Gy - Gray
- T3 - Thyronine
- T4 - Thyroxine
- TSH – Thyroid-stimulating hormone
- TSHr – Thyroid-stimulating hormone receptor
- GAG – glycosaminoglycans
- GO - Graves' ophthalmopathy
- PTD - Pretibial dermatopathy

Results of a study including 178 patients with thyroidal dermopathy showed that: only 3% of patients provided no anamnestic data and were without signs of ophthalmopathy; mild ophthalmopathy was recorded in 41% of patients, moderate in 31% and severe in 15.2%; optic neuropathy was established in 9.4% of patients with dermopathy (18). In the same study, 93.3% of patients suffered from pretibial dermopathy, 3.9% from pretibial and foot dermopathy, and 1.19% had pretibial and upper extremity dermopathy. Dermopathy manifested as non-pitting edema in 43.3% of patients, plaque dermopathy in 27.0%, nodular in 18.52% and elephantiasis in 2.8% (18). Although much less commonly, dermopathy may affect hands, arms, shoulders, head and neck, as well as sites of trauma, surgery, scars or skin grafts (5, 19, 20).

The thyroid acropathy is a rare extrathyroidal manifestation (2) with prevalence of 0.8 – 1.0%. It is a marker for severe thyroid-associated autoimmune process and ophthalmopathy (21).

The most common manifestation of acropathy is clubbing of fingers and toenails (18) - so called Hippocratic nails (1). It is characterized by clubbing and swelling of fingers, with periosteal reaction on distal bones (9). Radiography shows fusiform finger swelling and subperiosteal formation on metacarpal bones, proximal and middle phalanx and metatarsal bones and proximal phalanx of the toes (18).

In the diagnosis of Graves’ disease, it is very important to control T3, T4 and TSH. Sometimes TSH is too low to be measured (2).

Histopathological changes are also characteristic and include mucin deposits, especially in the lower dermis.

The first step in the treatment of Graves’ disease is elimination of risk factors, if possible. Obesity is an important risk for the development of venous stasis and edema in the lower extremities, affecting the severity of pretibial myxedema (9). Smoking has also been established as a marker of severity of autoimmune manifestations in Graves’ disease (22).

Thyroid dysfunction therapy is done by endocrinologists and surgeons. It includes thyreosuppressants, medications for hormone suppression, and two forms of ablation therapy: surgical and using radioactive iodine (2).

In order to prevent extrathyroidal manifestations that may develop in some patients after therapy by radioactive iodine, concomitant corticosteroid therapy is applied (9). Apart from systemic corticosteroids, systemic immunomodulators are also used in the treatment of ophthalmopathy (cyclosporine and intravenous immunoglobulins); plasmapheresis and somastatin analogues such as octreotide (insulin-like growth factor type-1-antagonist); systemic immunomodulators are used for regression of skin lesions (18); radiation therapy is also used, while surgical orbital decompression is used in the correction of exophthalmos, and surgery of extraocular muscles in the correction of diplopia (23).
Egzoftalmus, pretibijalni miksedom i akropatija – trijada prisutna kod obolelog od Grejsove bolesti

Sažetak
Uvod: Grejsova bolest je hronična autoimunska bolest koju karakteriše difuzna struma sa hipertireozom, oftalmopatijom i dermopatijom. Hipertireoza se javlja kod 1-2% žena mlađih od 40 godina, dok je kod muškaraca reda za oko deset puta. Javlja se kod 0,3% pripadnika opšte populacije, a čak 4,3% ima supkliničku formu bolesti. Oftalmopatija, dermopatija, pa akropatija. Retko pretibijalni miksedom može da bude inicijalni simptom Grejsove bolesti. Oftalmopatija se javlja kod 30% bolesnika sa Grejsovoj bolešću, dermopatija kod 4%, a akropatija kod 1% bolesnika. Simptomi bolesti se javljaju nezavisno od produkcije tiroidnih hormona. Kompletna trijada ekstratiroidnih manifestacija pod imenom EMO sindrom (egzoftalmus, pretibijalni miksedom, osteoartropatija) u sklopu Grejsove bolesti retko se registruje.

References
Prikaz slučaja: U ovom radu prikazan je bolesnik star 39 godina koji je u 35. i 36. godini lečen citostaticima i zračnom terapijom (supradijafragmalna regija) zbog Hočkinove bolesti i nakon toga doveden u stanje remisije. Dve godine kasnije javili su se opšti simptomi Grejsove bolesti i oftalmopatija. Tada su registrovane povišene vrednosti tirostimulišućeg hormona TSH. Četiri meseca od početka bolesti registrovane su i povišene vrednosti tiroksina (T4) i snižene vrednosti TSH. Dijagnoza EMO sindroma je potvrđena radiološkim i patohistološkim analizama. Ordinirana je peroralna terapija tiamazolom, uz intralezionalno injiciranje difuzne, akropatije, kao i na koži transplantiranih graftova.

Tiroidna akropatija je retka kasna ekstratiroidna manifestacija, sa prevalencijom 0,8–1 % i predstavlja marker za težinu autoimunog procesa i marker za težinu udružene oftalmopatije. Najčešća manifestacija akropatije jeste pojava maljičastih prstiju šaka i stopala: Hipokratovi prstii. Koža prstiju može biti otečena i zategnuta, sa prisutnom periostalnom reakcijom na distalnim kostima. Radiografski se konstatuje fuziformni otok tkiva prstiju i subperiostalna formacija na metakarpalnim kostima, proksimalnim i srednjim falangama prstiju ruka i metaterzalnim kostima i proksimalnim falangama prstiju nog. U dijagnostici Grejsove bolesti vrlo važno je kontrolisanje trijodtironina (T3), naročito T4 hormona i TSH. Nekad je TSH izrazito nizak i nemerljiv.

Patohistološke promene su takođe karakteristične i podrazumevaju obnašanje depoizita mucina, naročito u donjem dermisu. Lečenje tiroidne disfunkcije spada u domen endokrinologa i hirurga; podrazumeva predmetni trijodtironina (T3), lekova za smanjenje produkciune hormona i dva vida ablativne terapije, hirurške i zasnovane na primeni radioktivnog joda. U lečenju oftalmopatije, pored sistemskih kortikosteroida, koriste se i sistemski imunomodulatori (ciklosporin i intravenski imunoglobulini), plazmafereza i oktreotid (eng. octreotide: insulin-like growth factor type 1- antagonist). Takođe se primenjuju: radioterapija, hirurška dekompresija orbite, koja koriguje egzofalalnsus, i hirurška ekstraokularnih mišića koja koriguje diplopiju. U lečenju lakših oblika pretibijalnog miksedema primenjuju se potenti lokalni kortikosteroidi pod okluzijom. Kod izrazitih formi miksedema mogu se primeniti: kortikosteroidi intralezionalno, što je dalo pozitivne efekte i kod našeg bolesnika; takođe se koristi kompresivna i kompletna dekongestivna fizioterapija; CO2 laser; a u težim slučajevima i hirurška ablacija. U lečenju oftalmopatije, pored sistemskih kortikosteroida, koriste se i sistemski imunomodulatori (ciklosporin i intravenski imunoglobulini), plazmafereza i oktreotid (eng. octreotide: insulin-like growth factor type 1- antagonist). Takođe se primenjuju: radioterapija, hirurška dekompresija orbite, koja koriguje egzofalalnsus, i hirurška ekstraokularnih mišića koja koriguje diplopiju.